Novo Nordisk invests in facility expansion at production site in Denmark
Production site in Måløv, Denmark manufactures products for oral diabetes treatment Rybelsus
Read More
Tag: Rybelsus
UK launch for Novo’s new diabetes pill
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
Read More
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
